Intrahepatic cholangiocarcinoma: risk factors affecting survival of operated patients.

Intrahepatický cholangiokarcinom: rizikové faktory přežití operovaných nemocných.

Journal

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti
ISSN: 0035-9351
Titre abrégé: Rozhl Chir
Pays: Czech Republic
ID NLM: 9815441

Informations de publication

Date de publication:
2022
Historique:
entrez: 18 10 2022
pubmed: 19 10 2022
medline: 21 10 2022
Statut: ppublish

Résumé

The aim of this study was to evaluate the results of surgical treatment of intrahepatic cholangiocarcinoma (IHCHCA) in terms of overall survival and disease-free survival, and to analyse and find potential prognostic factors affecting overall survival and disease-free survival. Retrospective evaluation was performed of consecutively enrolled patients operated for IHCHCA from January 2005 to January 2022 (17 years) had undergone surgery. During the monitored period, 38 surgical procedures were performed, of which liver resection was done in 25 cases (65.8%). The 5-year survival in the radically resected group was 44%, and the 5-year disease-free survival was 32%. Based on univariate and multivariate analysis, radicality of surgery (p=0.01116) and lymph node involvement (p=0.00576) were assessed as negative prognostic factors for overall survival. Radicality of surgery (p=0.018) and administration of adjuvant chemotherapy (p=0.044) were significant negative prognostic factors affecting disease-free survival. However, they lost their significance in the multivariate analysis. Radical surgical resection of the liver remains an essential treatment option for intrahepatic cholangiocarcinoma aimed at achieving a radical procedure with microscopically negative margins. cholangiocarcinoma, resection, recurrence, survival.

Identifiants

pubmed: 36257803
pii: 132172
doi: 10.33699/PIS.2022.101.9.443-451
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

443-451

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH